A new site has been launched to present genomic markers of sensitivity to anti-cancer compounds screened across a 1000+ cancer cell line resource.
cancerRxgene.org has enhanced user interfaces making it simple to access our data and analyses. All of the institute's genetic and drug sensitivity data, including results from future screening, are freely available and can be downloaded. The website is set to be regularly updated as new data becomes available.
Drug sensitivity data
Sanger Institute, part of the Wellcome Trust, have released sensitivity data for 130 anti-cancer drugs screened across a large subset of their cell line resource.
Drug sensitivity data for more than 600 cell lines have been correlated with extensive genetic data to identify genomic events associated with sensitivity and resistance.
This is the largest publicly available dataset of its type, representing over 48,000 drug-cell line combinations, and provides a comprehensive view of the genomics of drug sensitivity in cancer.
Cancer cell line resource
The 1000+ cell line resource represents the spectrum of common and rare types of adult and childhood cancers of epithelial, mesenchymal and haematopoietic origin.
Cell lines have been subjected to sequencing of the full coding exons of 64 commonly mutated cancer genes, genome-wide analysis of copy number gain and loss using Affymetrix SNP6.0 microarrays, and expression profiling of 14,500 genes using Affymetrix HT-U133A microarrays.
The presence of seven commonly rearranged cancer genes and of microsatellite instability (MSI) has also been investigated. Genetic data for the cell lines are available through our website and the Cancer Genome Project webpages.
The cell lines have been submitted for whole-exome sequencing and this data will soon be available.
Integration with COSMIC
The analyses have been integrated with the Catalogue of Somatic Mutations in Cancer (COSMIC) database providing a comprehensive resource linking somatic mutations and other information related to cancer with drug sensitivity information.
Data for the following drugs are included in this release:
681640, 17-AAG, A-443654, A-769662, A-770041, ABT-263, ABT-888, AICAR, AKT inhibitor VIII, AMG-706, AP-24534, AS601245, ATRA, AUY922, Axitinib, AZ628, AZD-0530, AZD-2281, AZD-6244, AZD-6482, AZD-7762, AZD-8055, BAY613606, Bexarotene, BI-2536, BI-D1870, BIBW2992, Bicalutamide, BIRB 0796, Bleomycin, BMS-509744, BMS-536924, BMS-754807, Bortezomib, Bosutinib, Bryostatin 1, BX-795, Camptothecin, CEP-701, CGP-082996, CGP-60474, CHIR-99021, CI-1040, Cisplatin, CMK, Cyclopamine, Cytarabine, Dasatinib, DMOG, Docetaxel, Doxorubicin, Elesclomol, Embelin, Epothilone B, Erlotinib, Etoposide, FH535, FTI-277, GDC-0449, GDC0941, Gefitinib, Gemcitabine, GNF-2, GSK-650394, GSK269962A, GW 441756, GW843682X, Imatinib, IPA-3, JNK Inhibitor VIII, JNK-9L, JW-7-52-1, KIN001-135, KU-55933, Lapatinib, Lenalidomide, LFM-A13, Metformin, Methotrexate, MG-132, Midostaurin, Mitomycin C, MK-2206, MS-275, Nilotinib, NSC-87877, NU-7441, Nutlin-3a, NVP-BEZ235, NVP-TAE684, Obatoclax Mesylate, OSI-906, PAC-1, Paclitaxel, Parthenolide, Pazopanib, PD-0325901, PD-0332991, PD-173074, PF-02341066, PF-562271, PHA-665752, PLX4720, Pyrimethamine, QS11, Rapamycin, RDEA119, RO-3306, Roscovitine, S-Trityl-L-cysteine, Salubrinal, SB216763, SB590885, Shikonin, SL 0101-1, Sorafenib, Sunitinib, Temsirolimus, Thapsigargin, Tipifarnib, Vinblastine, Vinorelbine, Vorinostat, VX-680, VX-702, WH-4-023, WZ-1-84, XMD8-85, Z-LLNle-CHO, ZM-447439
Source: Cancer Genome Project
(24 Jan 2017)